Attention deficit hyperactivity disorder (ADHD) is a听condition that affects people's behaviour. People with ADHD can seem restless, may have trouble concentrating and may act on impulse.
The global Attention Deficit and Hyperactivity Disorder market was valued at US$ 19160 million in 2023 and is anticipated to reach US$ 30770 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The Attention Deficit and Hyperactivity Disorder (ADHD) market is driven by the rising awareness of the disorder and its diagnosis, coupled with the increasing prevalence of ADHD among children and adults. ADHD is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity. The growing recognition of the impact of ADHD on daily life, educational performance, and workplace productivity contributes to market growth as individuals and healthcare providers seek effective treatment options. Moreover, advancements in diagnostic methods, therapy approaches, and medication options align with improved management of ADHD symptoms. However, the market also faces challenges, including accurate diagnosis and tailoring treatment plans to individual patient needs. Additionally, addressing concerns about overdiagnosis and appropriate medication usage can pose obstacles for healthcare professionals. To succeed, stakeholders must focus on providing comprehensive assessment and tailored interventions, fostering public awareness, and addressing the challenges to meet the increasing demand for accurate diagnosis and effective management of ADHD.
This report aims to provide a comprehensive presentation of the global market for Attention Deficit and Hyperactivity Disorder, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention Deficit and Hyperactivity Disorder.
Report Scope
The Attention Deficit and Hyperactivity Disorder market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Attention Deficit and Hyperactivity Disorder market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attention Deficit and Hyperactivity Disorder companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Segment by Type
Stimulant
Non-stimulant
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention Deficit and Hyperactivity Disorder companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention Deficit and Hyperactivity Disorder Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Application
1.3.1 Global Attention Deficit and Hyperactivity Disorder Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Attention Deficit and Hyperactivity Disorder Market Perspective (2019-2030)
2.2 Attention Deficit and Hyperactivity Disorder Growth Trends by Region
2.2.1 Global Attention Deficit and Hyperactivity Disorder Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Attention Deficit and Hyperactivity Disorder Historic Market Size by Region (2019-2024)
2.2.3 Attention Deficit and Hyperactivity Disorder Forecasted Market Size by Region (2025-2030)
2.3 Attention Deficit and Hyperactivity Disorder Market Dynamics
2.3.1 Attention Deficit and Hyperactivity Disorder Industry Trends
2.3.2 Attention Deficit and Hyperactivity Disorder Market Drivers
2.3.3 Attention Deficit and Hyperactivity Disorder Market Challenges
2.3.4 Attention Deficit and Hyperactivity Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Attention Deficit and Hyperactivity Disorder Players by Revenue
3.1.1 Global Top Attention Deficit and Hyperactivity Disorder Players by Revenue (2019-2024)
3.1.2 Global Attention Deficit and Hyperactivity Disorder Revenue Market Share by Players (2019-2024)
3.2 Global Attention Deficit and Hyperactivity Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Attention Deficit and Hyperactivity Disorder Revenue
3.4 Global Attention Deficit and Hyperactivity Disorder Market Concentration Ratio
3.4.1 Global Attention Deficit and Hyperactivity Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention Deficit and Hyperactivity Disorder Revenue in 2023
3.5 Attention Deficit and Hyperactivity Disorder Key Players Head office and Area Served
3.6 Key Players Attention Deficit and Hyperactivity Disorder Product Solution and Service
3.7 Date of Enter into Attention Deficit and Hyperactivity Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Attention Deficit and Hyperactivity Disorder Breakdown Data by Type
4.1 Global Attention Deficit and Hyperactivity Disorder Historic Market Size by Type (2019-2024)
4.2 Global Attention Deficit and Hyperactivity Disorder Forecasted Market Size by Type (2025-2030)
5 Attention Deficit and Hyperactivity Disorder Breakdown Data by Application
5.1 Global Attention Deficit and Hyperactivity Disorder Historic Market Size by Application (2019-2024)
5.2 Global Attention Deficit and Hyperactivity Disorder Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Attention Deficit and Hyperactivity Disorder Market Size (2019-2030)
6.2 North America Attention Deficit and Hyperactivity Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Attention Deficit and Hyperactivity Disorder Market Size by Country (2019-2024)
6.4 North America Attention Deficit and Hyperactivity Disorder Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Attention Deficit and Hyperactivity Disorder Market Size (2019-2030)
7.2 Europe Attention Deficit and Hyperactivity Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Attention Deficit and Hyperactivity Disorder Market Size by Country (2019-2024)
7.4 Europe Attention Deficit and Hyperactivity Disorder Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Attention Deficit and Hyperactivity Disorder Market Size (2019-2030)
8.2 Asia-Pacific Attention Deficit and Hyperactivity Disorder Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Attention Deficit and Hyperactivity Disorder Market Size by Region (2019-2024)
8.4 Asia-Pacific Attention Deficit and Hyperactivity Disorder Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Attention Deficit and Hyperactivity Disorder Market Size (2019-2030)
9.2 Latin America Attention Deficit and Hyperactivity Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Attention Deficit and Hyperactivity Disorder Market Size by Country (2019-2024)
9.4 Latin America Attention Deficit and Hyperactivity Disorder Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Attention Deficit and Hyperactivity Disorder Market Size (2019-2030)
10.2 Middle East & Africa Attention Deficit and Hyperactivity Disorder Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Attention Deficit and Hyperactivity Disorder Market Size by Country (2019-2024)
10.4 Middle East & Africa Attention Deficit and Hyperactivity Disorder Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Attention Deficit and Hyperactivity Disorder Introduction
11.1.4 Takeda Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.1.5 Takeda Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Attention Deficit and Hyperactivity Disorder Introduction
11.2.4 Johnson & Johnson Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Attention Deficit and Hyperactivity Disorder Introduction
11.3.4 Novartis Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Attention Deficit and Hyperactivity Disorder Introduction
11.4.4 Eli Lilly Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Tris Pharma
11.5.1 Tris Pharma Company Detail
11.5.2 Tris Pharma Business Overview
11.5.3 Tris Pharma Attention Deficit and Hyperactivity Disorder Introduction
11.5.4 Tris Pharma Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.5.5 Tris Pharma Recent Development
11.6 Neos Therapeutics
11.6.1 Neos Therapeutics Company Detail
11.6.2 Neos Therapeutics Business Overview
11.6.3 Neos Therapeutics Attention Deficit and Hyperactivity Disorder Introduction
11.6.4 Neos Therapeutics Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.6.5 Neos Therapeutics Recent Development
11.7 Mallinckrodt
11.7.1 Mallinckrodt Company Detail
11.7.2 Mallinckrodt Business Overview
11.7.3 Mallinckrodt Attention Deficit and Hyperactivity Disorder Introduction
11.7.4 Mallinckrodt Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.7.5 Mallinckrodt Recent Development
11.8 Amneal Pharmaceuticals
11.8.1 Amneal Pharmaceuticals Company Detail
11.8.2 Amneal Pharmaceuticals Business Overview
11.8.3 Amneal Pharmaceuticals Attention Deficit and Hyperactivity Disorder Introduction
11.8.4 Amneal Pharmaceuticals Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.8.5 Amneal Pharmaceuticals Recent Development
11.9 Noven Pharmaceuticals
11.9.1 Noven Pharmaceuticals Company Detail
11.9.2 Noven Pharmaceuticals Business Overview
11.9.3 Noven Pharmaceuticals Attention Deficit and Hyperactivity Disorder Introduction
11.9.4 Noven Pharmaceuticals Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.9.5 Noven Pharmaceuticals Recent Development
11.10 Purdue Parma
11.10.1 Purdue Parma Company Detail
11.10.2 Purdue Parma Business Overview
11.10.3 Purdue Parma Attention Deficit and Hyperactivity Disorder Introduction
11.10.4 Purdue Parma Revenue in Attention Deficit and Hyperactivity Disorder Business (2019-2024)
11.10.5 Purdue Parma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
听
听
*If Applicable.